{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T10:24:36Z","timestamp":1794306276153,"version":"4.9.0"},"reference-count":27,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,11,14]],"date-time":"2023-11-14T00:00:00Z","timestamp":1699920000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004622","name":"KWF Kankerbestrijding","doi-asserted-by":"publisher","award":["2017-2\/11179"],"award-info":[{"award-number":["2017-2\/11179"]}],"id":[{"id":"10.13039\/501100004622","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004622","name":"KWF Kankerbestrijding","doi-asserted-by":"publisher","award":["KUN 2013-5926"],"award-info":[{"award-number":["KUN 2013-5926"]}],"id":[{"id":"10.13039\/501100004622","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","euoncology.europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Oncology"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1016\/j.euo.2023.11.007","type":"journal-article","created":{"date-parts":[[2023,11,22]],"date-time":"2023-11-22T17:59:50Z","timestamp":1700675990000},"page":"829-837","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Health-related Quality of Life During the First 4 Years After Non\u2013Muscle-invasive Bladder Cancer Diagnosis: Results of a Large Multicentre Prospective Cohort"],"prefix":"10.1016","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8424-7638","authenticated-orcid":false,"given":"Ivy","family":"Beeren","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nena E.","family":"Klerks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katja K.","family":"Aben","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorg R.","family":"Oddens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Alfred","family":"Witjes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lambertus A.","family":"Kiemeney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8178-2125","authenticated-orcid":false,"given":"Alina","family":"Vrieling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euo.2023.11.007_b0005","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.eururo.2015.06.045","article-title":"EORTC nomograms and risk groups for predicting recurrence, progression, and disease-specific and overall survival in non-muscle-invasive stage Ta-T1 urothelial bladder cancer patients treated with 1\u20133 years of maintenance bacillus Calmette-Guerin","volume":"69","author":"Cambier","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2023.11.007_b0010","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1097\/JU.0000000000000593","article-title":"Use and validation of the AUA\/SUO risk grouping for nonmuscle invasive bladder cancer in a contemporary cohort","volume":"203","author":"Ritch","year":"2020","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2023.11.007_b0015","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.eururo.2021.08.010","article-title":"European Association of Urology guidelines on non-muscle-invasive bladder cancer (Ta, T1, and carcinoma in situ)","volume":"81","author":"Babjuk","year":"2022","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2023.11.007_b0020","doi-asserted-by":"crossref","first-page":"E21","DOI":"10.1097\/NCC.0000000000000606","article-title":"Quality of life in non-muscle-invasive bladder cancer survivors: a systematic review","volume":"42","author":"Jung","year":"2019","journal-title":"Cancer Nurs"},{"key":"10.1016\/j.euo.2023.11.007_b0025","doi-asserted-by":"crossref","first-page":"2737","DOI":"10.21037\/tau-20-1333","article-title":"Quality of life in patients undergoing surveillance for non-muscle invasive bladder cancer-a systematic review","volume":"10","author":"Nayak","year":"2021","journal-title":"Transl Androl Urol"},{"key":"10.1016\/j.euo.2023.11.007_b0030","doi-asserted-by":"crossref","first-page":"10825","DOI":"10.3390\/ijerph191710825","article-title":"Impact of effective intravesical therapies on quality of life in patients with non-muscle invasive bladder cancer: a systematic review","volume":"19","author":"Yuen","year":"2022","journal-title":"Int J Environ Res Public Health"},{"key":"10.1016\/j.euo.2023.11.007_b0035","doi-asserted-by":"crossref","first-page":"e030396","DOI":"10.1136\/bmjopen-2019-030396","article-title":"The UroLife study: protocol for a Dutch prospective cohort on lifestyle habits in relation to non-muscle-invasive bladder cancer prognosis and health-related quality of life","volume":"9","author":"de Goeij","year":"2019","journal-title":"BMJ Open"},{"key":"10.1016\/j.euo.2023.11.007_b0040","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","article-title":"The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology","volume":"85","author":"Aaronson","year":"1993","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.euo.2023.11.007_b0045","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1016\/j.eururo.2014.02.034","article-title":"Validation and reliability testing of the EORTC QLQ-NMIBC24 questionnaire module to assess patient-reported outcomes in non-muscle-invasive bladder cancer","volume":"66","author":"Blazeby","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2023.11.007_b0050","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/s41687-021-00372-4","article-title":"Validation and reliability of the Dutch version of the EORTC QLQ-NMIBC24 questionnaire module for patients with non-muscle-invasive bladder cancer","volume":"5","author":"Ripping","year":"2021","journal-title":"J Patient Reported Outcomes"},{"key":"10.1016\/j.euo.2023.11.007_b0055","series-title":"EORTC QLQ-C30 scoring manual","author":"Fayers","year":"2001"},{"key":"10.1016\/j.euo.2023.11.007_b0060","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1002\/art.10993","article-title":"The Self-Administered Comorbidity Questionnaire: a new method to assess comorbidity for clinical and health services research","volume":"49","author":"Sangha","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.euo.2023.11.007_b0065","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.ajcnut.2022.12.022","article-title":"Adherence to lifestyle recommendations after non-muscle invasive bladder cancer diagnosis and risk of recurrence","volume":"117","author":"van Zutphen","year":"2023","journal-title":"Am J Clin Nutr"},{"key":"10.1016\/j.euo.2023.11.007_b0070","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.eururo.2019.08.016","article-title":"European Association of Urology guidelines on non-muscle-invasive bladder cancer (TaT1 and carcinoma in situ)\u20142019 update","volume":"76","author":"Babjuk","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2023.11.007_b0075","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1080\/0284186X.2018.1481293","article-title":"Reference data of the EORTC QLQ-C30 questionnaire: five consecutive annual assessments of approximately 2000 representative Dutch men and women","volume":"57","author":"Mols","year":"2018","journal-title":"Acta Oncol"},{"key":"10.1016\/j.euo.2023.11.007_b0080","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jclinepi.2019.10.003","article-title":"Thresholds for clinical importance were established to improve interpretation of the EORTC QLQ-C30 in clinical practice and research","volume":"118","author":"Giesinger","year":"2020","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.euo.2023.11.007_b0085","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1179\/1973947813Y.0000000126","article-title":"The quality of life in patients during intravesical treatment and correlation with local symptoms","volume":"26","author":"Wei","year":"2014","journal-title":"J Chemother"},{"key":"10.1016\/j.euo.2023.11.007_b0090","first-page":"9480","article-title":"Health-related quality of life after BCG or MMC induction for non-muscle invasive bladder cancer","volume":"25","author":"Siracusano","year":"2018","journal-title":"Can J Urol"},{"key":"10.1016\/j.euo.2023.11.007_b0095","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/j.juro.2013.03.097","article-title":"The impact of intravesical gemcitabine and 1\/3 dose bacillus Calmette-Guerin instillation therapy on the quality of life in patients with nonmuscle invasive bladder cancer: results of a prospective, randomized, phase II trial","volume":"190","author":"Gontero","year":"2013","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2023.11.007_b0100","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1111\/j.1442-2042.2010.02584.x","article-title":"Maintenance intravesical bacillus Calmette-Gu\u00e9rin instillation for Ta, T1 cancer and carcinoma in situ of the bladder: randomized controlled trial by the BCG Tokyo Strain Study Group","volume":"17","author":"Koga","year":"2010","journal-title":"Int J Urol"},{"key":"10.1016\/j.euo.2023.11.007_b0105","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1016\/j.ejca.2012.02.059","article-title":"Evidence-based guidelines for interpreting change scores for the European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30","volume":"48","author":"Cocks","year":"2012","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.euo.2023.11.007_b0110","doi-asserted-by":"crossref","first-page":"40","DOI":"10.4143\/crt.2016.594","article-title":"Development and validation of the Korean version of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire for patients with non-muscle invasive bladder cancer\u2014EORTC QLQ-NMIBC24","volume":"50","author":"Park","year":"2018","journal-title":"Cancer Res Treat"},{"key":"10.1016\/j.euo.2023.11.007_b0115","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/j.eururo.2021.01.032","article-title":"Quality of life after bladder cancer: a cross-sectional survey of patient-reported outcomes","volume":"79","author":"Catto","year":"2021","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2023.11.007_b0120","doi-asserted-by":"crossref","first-page":"19.e7","DOI":"10.1016\/j.urolonc.2014.09.012","article-title":"Quality of life in patients with non-muscle-invasive bladder cancer: one-year results of a multicentre prospective cohort study","volume":"33","author":"Schmidt","year":"2015","journal-title":"Urol Oncol"},{"key":"10.1016\/j.euo.2023.11.007_b0125","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1111\/bju.14047","article-title":"Impact of bladder cancer on health-related quality of life","volume":"121","author":"Smith","year":"2018","journal-title":"BJU Int"},{"key":"10.1016\/j.euo.2023.11.007_b0130","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.urology.2018.11.038","article-title":"Nonmuscle invasive bladder cancer influences physical health related quality of life and urinary incontinence","volume":"125","author":"Brisbane","year":"2019","journal-title":"Urology"},{"key":"10.1016\/j.euo.2023.11.007_b0135","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1200\/JCO.2010.28.0107","article-title":"Evidence-based guidelines for determination of sample size and interpretation of the European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30","volume":"29","author":"Cocks","year":"2011","journal-title":"J Clin Oncol"}],"container-title":["European Urology Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931123002523?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931123002523?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T09:34:12Z","timestamp":1794303252000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2588931123002523"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":27,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["S2588931123002523"],"URL":"https:\/\/doi.org\/10.1016\/j.euo.2023.11.007","relation":{},"ISSN":["2588-9311"],"issn-type":[{"value":"2588-9311","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Health-related Quality of Life During the First 4 Years After Non\u2013Muscle-invasive Bladder Cancer Diagnosis: Results of a Large Multicentre Prospective Cohort","name":"articletitle","label":"Article Title"},{"value":"European Urology Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euo.2023.11.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s). Published by Elsevier B.V. on behalf of European Association of Urology.","name":"copyright","label":"Copyright"}]}}